RARA CRAFT DATABASE for FDA Medical Devices
PMAP210014

FDA DEVICE FACTS

SLENDER Sirolimus-Eluting Coronary Stent Integrated Delivery System and DIRECT Sirolimus-Eluting Coronary Stent Rapid Ex

Advanced Bifurcation Systems, Inc.

Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。

DECISION DATEDecember 13, 2021PRODUCT CODENIQ

Indications for use

The Svelte SLENDER Sirolimus-Eluting Coronary Stent Integrated Delivery System (Svelte SLENDER IDS) is indicated for improving coronary artery luminal diameter in patients with symptomatic heart disease due to atherosclerotic lesions ≤ 24 mm in length in native coronary arteries with ≥ 2.25 mm to ≤ 4.00 mm reference vessel diameters, using direct stenting or pre-dilatation interventional techniques. The Svelte DIRECT Sirolimus-Eluting Coronary Stent Rapid Exchange Delivery System (Svelte DIRECT RX) is indicated for improving coronary artery luminal diameter in patients with symptomatic heart disease due to atherosclerotic lesions ≤ 34 mm in length in native coronary arteries with ≥ 2.25 mm to ≤ 4.00 mm reference vessel diameters, using direct stenting or pre-dilatation interventional techniques.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 2, 2026